Skip to main content

Advertisement

Log in

Preparing pathology for precision medicine: challenges and opportunities

  • Original Article
  • Published:
Virchows Archiv Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Hallworth MJ (2011) The ‘70% claim’: what is the evidence base? Ann Clin Biochem 48:487–488

    Article  PubMed  Google Scholar 

  2. Badrich T (2013) Evidence-based laboratory medicine. Clin Biochem Rev 34:43–46

    Google Scholar 

  3. Vogelstein B et al (2013) Cancer genome landscapes. Science 339(6127):1546–1558

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  4. National Center for Biotechnology Information (2014) Gene: KMT2D lysine (K)-specific methyltransferase 2D [Homo sapiens (human)]. Gene database. Available from: http://www.ncbi.nlm.nih.gov/gene/8085.

  5. Louis DN, Perry A, Reifenberger G, von Deimling F-BD, Cavenee WK, Ohgaki H, Weistler OD, Kleihues P, Ellison DW (2016) The 2016 World Health Organization classification of tumors of the central nervous system: a summary. Acta Neuropathol 131:803–820

    Article  PubMed  Google Scholar 

  6. Swerdlow SH, Campo E, Pileri SA, Harris NL, Stein H, Siebert R, Advani R, Ghielmini M, Salles GA, Zelenetz AD, Jaffe ES (2016) The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood 127:2375–2390. doi:10.1182/blood-2016-01-643569

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. Wang HL, Lopategui J, Amin MB et al (2010) KRAS mutation testing in human cancers: the pathologist’s role in the era of personalized medicine. Adv Anat Pathol 17:23–32

    CAS  PubMed  Google Scholar 

  8. Lièvre A, Bachet JB, Le Corre D, Boige V, Landi B, Emile JF, Côté JF, Tomasic G, Penna C, Ducreux M, Rougier P, Penault-Llorca F, Laurent-Puig P (2006) KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. Cancer Res 66(8):3992–3995. doi:10.1158/0008-5472.CAN-06-0191. PMID16618717

    Article  PubMed  Google Scholar 

  9. Di Fiore F, Le Pessot F, Lamy A, et al. KRAS mutation is highly predictive of cetuximab resistance in metastatic colorectal cancer. J Clin Oncol, 2007 ASCO Annual Meeting Proc.; vol 25, No 18S (June 20 Supplement), p 2007:10502

  10. Kamel-Reid S, Zhang T, Persons DL, Molecular Oncology Resource Committee of the College of American Pathologists et al (2012) Validation of KRAS testing for anti-EGFR therapeutic decisions for patients with metastatic colorectal carcinoma. Arch Pathol Lab Med 136:26–32. doi:10.5858/arpa.2011-0220-OA http://www.ncbi.nlm.nih.gov/pubmed/22208484

    Article  CAS  PubMed  Google Scholar 

  11. Allegra CJ, Jessup JM, Somerfield MR et al (2009) American Society of Clinical Oncology provisional clinical opinion: testing for KRAS mutations in patients with metastatic colorectal carcinoma to predict response to anti-epidermal growth factor receptor monoclonal antibody therapy. J Clin Oncol 27:2091–2095

    Article  PubMed  Google Scholar 

  12. National Comprehensive Cancer Network Guidelines on Colon and Rectal Cancers. NCCN, PA, USA (2008). Practice guidelines established for KRAS mutation testing in colorectal cancer

  13. Evaluation of Genomic Applications in Practice and Prevention (EGAPP) Working Group (2013) Recommendations from the EGAPP working group: can testing of tumor tissue for mutations in EGFR pathway downstream effector genes in patients with metastatic colorectal cancer improve health outcomes by guiding decisions regarding anti-EGFR therapy? Genet Med 15(7):517–527. doi:10.1038/gim.2012.184

    Article  Google Scholar 

  14. Allegra CJ, Rumble RB, Hamilton SR, Roach N, Hantel, A, Schilsky RL (2015) Extended RAS gene mutation testing in metastatic colorectal carcinoma to predict response to anti–epidermal growth factor receptor monoclonal antibody therapy: ASCO Provisional Clinical Opinion Update 2015. doi:10.1200/JCO.2015.63.9674

  15. Tang W, Hu Z, Muallem H, Gulley ML (2012) Quality assurance of RNA expression profiling in clinical laboratories. J Molec Diagnostics 14:1–11. doi:10.1016/j.jmoldx.2011.09.003

    Article  CAS  Google Scholar 

  16. Mortensen MM, Høyer S, Lynnerup A-S, Ørntoft TF, Sørensen KD, Borre M, Dyrskjøt L (2015) Expression profiling of prostate cancer tissue delineates genes associated with recurrence after prostatectomy. Nature: Scientific Reports 5:16018. doi:10.1038/srep16018

    CAS  Google Scholar 

  17. Nielsen T, Wallden B, Schaper C, Ferree S, Liu S, Gao D, Barry G, Dowidar N, Maysuria M, Storhoff J (2014) Analytic validation of the PAM50-based Prosigna breast cancer prognostic gene signature assay and nCounter analysis system using formalin-fixed paraffin embedded breast tumor specimens. BMC Cancer 14:177 http://www.biomedcentral.com/1471-2407/14/177

    Article  PubMed  PubMed Central  Google Scholar 

  18. Wilhelm M, Schlegl J, Hahne H, Gholami AM, Lieberenz M, Savitski MM, Ziegler E, Butzmann L, Gessulat S, Marx H, Mathieson T, Lemeer S, Schnatbaum K, Reimer U, Wenschuh H, Mollenhauer M, Slotta-Huspenina J, Boese J-H, Bantscheff M, Gerstmair A, Faerber F, Kuster B (2014) Mass-spectrometry-based draft of the human proteome. Nature 509:582–587. doi:10.1038/nature13319

    Article  CAS  PubMed  Google Scholar 

  19. Mycancergenome.org

  20. Quail MA, Smith M, Copeland P, Otto TD, Harris SR, Connor TR, Bertoni A, Swerdlow HP, Gu Y (2012) A tale of three next generation sequencing platforms: comparison of ion torrent, Pacific BioScidences and Illumina MiSeq sequencers. BMC Genomics 13:341–354

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  21. Corless CL (2016) Next-generation sequencing in cancer diagnostics. J Molec Diagn 18:813–816

    Article  Google Scholar 

  22. Misura M, Zhang T, Sukhai MA, Thomas M, Garg S, Kamel-Reid S, Stockley TL (2016) Comparison of next generation sequencing panels and platforms for detection and verification of somatic tumor variants for clinical diagnostics. J. Molec. Diagn. 18:842–850

    Article  Google Scholar 

  23. Gargis AG, Kalman L, Bick DP, da Silva C, Dimmock DP, Funke BH, Gowrisankar S, Hegde MR, Kulkarni S, Mason CE, Nagarajan R, Voelkerding KV, Worthey EA, Aziz N, Barnes J, Bennett SF, Bisht H, Church DM, Dimitrova Z, Gargis SR, Hafez N, Hambuch T, Hyland FCL, Luna RA, MacCannell D (2015) Good laboratory practice for clinical next-generation sequencing informatics pipelines. Nat Biotechnol 33:689–693. doi:10.1038/nbt.3237

    Article  CAS  PubMed  Google Scholar 

  24. Lindeman NI, Cagle PT, Beasley MB, Chitale DA, Dacic S, Giaccone G et al (2013) Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors. Guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology. J Molec Diagn 15:415–453

    Article  CAS  Google Scholar 

  25. NCCN Clinical Practice Guidelines in Oncology: Non-Small Cell Lung Cancer v. 3.2017. www.nccn.org.

  26. Simon R, Roychowdhury S (2013) Implementing personalized cancer genomics in clinical trials. Nature 12:358–369

    CAS  Google Scholar 

  27. Training Residents in Genomics. (2012) www.pathologylearning.org/trig/resources

  28. https://www.ukneqas-molgen.org.uk/introduction

  29. Matthijs G, Souche E, Alders M, Corveleyn A, Eck S, Feensgra I, Race V, Sistermans E, Sturm M, Weiss M, Yntem H, Bakker E, Scheffer H, Bauer P (2016) Guidelines for diagnostic next-generation sequencing. European J Human Genetics 24:2–5

    Article  CAS  Google Scholar 

  30. Deans Z, Watson CM, Charlton R, et al. Practice Guidelines for Targeted Next Generation Sequencing Analysis and Interpretation. http://www.acgs.uk.com/media/983872/bpg_for_targeted_next_generation_sequencing_-_approved_dec_2015.pdf

  31. Joseph L, Cankovic M, Caughron S et al (2016) The spectrum of clinical utilities in molecular pathology testing procedures for inherited conditions and cancer. J Molec Pathol 5:605–619

    Google Scholar 

  32. Zehnbauer B, Lofton-Day C, Pfeifer J, Shaughnessy E, Goh L (2017) Diagnostic quality assurance pilot: a model to demonstrate comparative laboratory test performance with an oncology companion device assay. J Molec Diagn 19:1–3. doi:10.1016/j.jmoldx.2016.10.001

    Article  Google Scholar 

  33. http://www.tapestrynetworks.com/initiatives/healthcare/oncology-therapeutics-and-diagnostics/diagnostic-quality-assurance-pilot.cfm

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Karen L Kaul.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Kaul, K.L. Preparing pathology for precision medicine: challenges and opportunities. Virchows Arch 471, 141–146 (2017). https://doi.org/10.1007/s00428-017-2141-z

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00428-017-2141-z

Keywords

Navigation